Alpha 2.0
Login Register
» Articles » PMID: 32535976

Real-life Effectiveness and Short-term (16-week) Tolerance of Guselkumab for Psoriasis: a Belgian Retrospective Multicentre Study

Overview
Journal J Eur Acad Dermatol Venereol
Specialty Infectious Diseases
Date 2020 Jun 15
PMID 32535976
Citations 9
Authors
F Benhadou
P D Ghislain
F Guiot
F Willaert
V Del Marmol
J Lambert
R Soenen
H Fierens
M De La Brassinne
Affiliations
Soon will be listed here.
Citing Articles

Long-Term Efficacy, Safety, and Drug Survival of Guselkumab in Patients with Psoriasis: Real-World Data from the Czech Republic BIOREP Registry.

Hugo J, Kojanova M, Turkova B, Gkalpakiotis S Dermatol Ther (Heidelb). 2023; 13(3):787-801.

PMID: 36723775 PMC: 9890420. DOI: 10.1007/s13555-023-00893-4.

Anti-IL23 biologic therapies in the treatment of psoriasis: real-world experience versus clinical trials data.

Ruggiero A, Megna M, Fabbrocini G, Ocampo-Garza S Immunol Res. 2023; 71(3):328-355.

PMID: 36598647 PMC: 9811885. DOI: 10.1007/s12026-022-09356-y.

Effectiveness, survival and safety of guselkumab attending to basal characteristics in moderate-to-severe psoriatic patients: a cohort study.

Ruiz-Villaverde R, Rodriguez-Fernandez-Freire L, Armario-Hita J, Perez-Gil A, Vasquez Chinchay F, Galan-Gutierrez M F1000Res. 2022; 11:1178.

PMID: 36567685 PMC: 9755754. DOI: 10.12688/f1000research.122945.2.

Real-world effectiveness and safety of tildrakizumab in long-term treatment of plaque psoriasis: Results from the non-interventional, prospective, multicentre study TILOT.

Tsianakas A, Schwichtenberg U, Pierchalla P, Hinz T, Diemert S, Korge B J Eur Acad Dermatol Venereol. 2022; 37(1):85-92.

PMID: 36066998 PMC: 10087575. DOI: 10.1111/jdv.18572.

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence.

Ruggiero A, Picone V, Martora F, Fabbrocini G, Megna M Clin Cosmet Investig Dermatol. 2022; 15:1649-1658.

PMID: 35996400 PMC: 9392468. DOI: 10.2147/CCID.S364640.